miR-133b Promotes Esophageal Squamous Cell Carcinoma Metastasis

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Molecular-level biological changes are crucial for improving survival rates in esophageal squamous cell carcinoma (ESCC).
• Understanding the expression patterns of specific molecules can offer clinical insights into ESCC progression.
• This study focuses on microRNA-133b (miR-133b), M2 pyruvate kinase (PKM2), and signal transducer and activator of transcription 3 (STAT3) in ESCC.

Purpose of the Study:

• To analyze and elucidate the expression of miR-133b, PKM2, and STAT3 in ESCC tissues.
• To investigate the clinicopathological significance of these molecules in ESCC.
• To explore the potential regulatory relationship between miR-133b, PKM2, and STAT3 in ESCC.

Main Methods:

• In situ hybridization was employed to detect miR-133b expression in 72 ESCC patients and matched normal adjacent tissues (NAT).
• Immunohistochemistry was used to determine the tissue expression levels of PKM2 and STAT3.
• Correlation analysis was performed to assess the relationships between the expression of these molecules.

Main Results:

• miR-133b expression was significantly lower in ESCC compared to NAT (P=.003).
• PKM2 and STAT3 showed significantly higher positive expression levels in ESCC than in NAT (P=.000 for both).
• A negative correlation was observed between miR-133b and PKM2 (r=-0.515, P<.001), and between miR-133b and STAT3 (r=-0.314, P=.007). A positive correlation existed between PKM2 and STAT3 (r=0.771, P<.001).

Conclusions:

• Esophageal squamous cell carcinoma is characterized by the downregulation of miR-133b and upregulation of PKM2 and STAT3.
• The findings suggest that miR-133b may play an inhibitory role in ESCC by downregulating PKM2, potentially affecting the STAT3 signaling pathway.
• These molecular alterations highlight potential therapeutic targets for ESCC management.